Daniel R. Chevallard net worth and biography

Daniel Chevallard Biography and Net Worth

CFO of LENZ Therapeutics

Dan Chevallard joined LENZ Therapeutics in March 2024 as its Chief Financial Officer and is a respected corporate finance and strategic executive with significant experience in the biotechnology, pharmaceutical and diagnostic industries. Previously, Dan served as the Chief Operating Officer and Chief Financial Officer of Viracta Therapeutics. He joined Viracta in July 2019 as its Chief Financial Officer and prior to that, served as the Chief Financial Officer and principal financial officer at Regulus Therapeutics.

What is Daniel R. Chevallard's net worth?: The estimated net worth of Daniel R. Chevallard is at least $52.41 thousand as of November 7th, 2025. Chevallard owns 5,386 shares of LENZ Therapeutics stock worth more than $52,406 as of May 7th. This net worth evaluation does not reflect any other assets that Chevallard may own. Learn More about Daniel R. Chevallard's net worth.
How do I contact Daniel R. Chevallard?: The corporate mailing address for Chevallard and other LENZ Therapeutics executives is 611 Gateway Blvd Suite 120, SOUTH SAN FRANCISCO CA, 94080. LENZ Therapeutics can also be reached via phone at 650-484-0886 and via email at [email protected]. Learn More on Daniel R. Chevallard's contact information.
Has Daniel R. Chevallard been buying or selling shares of LENZ Therapeutics?: Daniel R. Chevallard has not been actively trading shares of LENZ Therapeutics over the course of the past ninety days. Most recently, on Friday, November 7th, Daniel R. Chevallard bought 2,198 shares of LENZ Therapeutics stock. The stock was acquired at an average cost of $22.76 per share, with a total value of $50,026.48. Following the completion of the transaction, the chief financial officer now directly owns 5,386 shares of the company's stock, valued at $122,585.36. Learn More on Daniel R. Chevallard's trading history.
Who are LENZ Therapeutics' active insiders?: LENZ Therapeutics' insider roster includes Daniel Chevallard (CFO), James McCollum (Director), and Shawn Olsson (Insider). Learn More on LENZ Therapeutics' active insiders.
Are insiders buying or selling shares of LENZ Therapeutics?: In the last twelve months, LENZ Therapeutics insiders bought shares 2 times. They purchased a total of 12,698 shares worth more than $289,321.48. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 10,000 shares worth more than $261,000.00. The most recent insider tranaction occured on November, 17th when insider Shawn Olsson sold 10,000 shares worth more than $261,000.00. Insiders at LENZ Therapeutics own 6.9% of the company. Learn More about insider trades at LENZ Therapeutics.
Information on this page was last updated on 11/17/2025.

Daniel R. Chevallard Insider Trading History at LENZ Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/7/2025	Buy	2,198	$22.76	$50,026.48	5,386

Daniel R. Chevallard Buying and Selling Activity at LENZ Therapeutics

LENZ Therapeutics Company Overview

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Today's Range

Now: $9.73

$9.36

$9.74

50 Day Range

MA: $10.55

$8.29

$13.68

2 Week Range

Now: $9.73

$8.25

$50.40

Volume

155,712 shs

Average Volume

988,183 shs

Market Capitalization

$305.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62